Pharma Spreads Its Bets On Multiple Modalities In Advanced Products
Executive Summary
Companies such as Novartis, Roche or Takeda are heavily invested in the advanced therapeutics field, usually spreading their bets across multiple modalities. The remaining challenges offer opportunities for the next wave of innovation to transform the field once again and make a dent in the larger market of common diseases and solid tumors.
You may also be interested in...
Janssen/Legend Plan Phased US Launch For BCMA-Targeting CAR-T Carvykti
Janssen priced the one-time autologous treatment at $465,000, well above the $419,500 list price for Bristol’s first-to-market CAR-T, but expects broad commercial and Medicare coverage.
Bayer Bids To Be A Winner In Cell & Gene Therapy
The last six weeks have seen the acquisition of AskBio, the launch of a dedicated cell and gene therapy unit and a CAR-T pact with Atara. Bayer is taking the space very seriously.
Bayer Boosts Gene Therapy Presence With AskBio Buy
After buying BlueRock Therapeutics outright last year, the Leverkusen-headquartered group has put down $2bn up front to acquire another cell and gene therapy specialist in Asklepios BioPharmaceutical.